肝脏缺血再灌注损伤的基因干预新靶点  

Novel targets for ischemia reperfusion injury therapy in the liver

作　　者：李玲[1] 陈彬尧 赵慧佳[1] 范志鹏 孙功鹏 董礼 乐江[2] 叶啟发[1] Li Ling;Chen Binyao;Zhao Huijia;Fan Zhipeng;Sun Gongpeng;Dong Li;Yue Jiang;Ye Qifa(Zhongnan Hospital of Wuhan University,Institute of Hepatobiliary Diseases of Wuhan University,Transplant Center of Wuhan University,Hubei Key Laboratory of Medical Technology on Transplantation,Wuhan 430071,China;Department of Pharmacology,Basic Medical School of Wuhan University,Wuhan 430071,China)

机构地区：[1]武汉大学中南医院武汉大学肝胆疾病研究院武汉大学移植医学中心移植医学技术湖北省重点实验室,武汉430071 [2]武汉大学基础医学院药理教研室,武汉430071

出　　处：《中华肝胆外科杂志》2019年第12期948-951,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：湖北省技术创新专项(2016ACA155);病毒学国家重点实验室开放研究基金(2018KF005);湖北省卫计委药护技和管理专项(WJ2017H0024)。

摘　　要：肝脏缺血再灌注损伤(IRI)常见于出血性休克、肝移植、肝脏外科手术患者,研究肝脏IRI特定基因靶点对临床预防和减轻肝损伤有重要意义。过氧化物酶体增殖物激活受体γ可以通过序列相似性家族3基因减轻肝脏IRI,发挥保护作用。同时,非编码RNA,包括微小RNA和长链非编码RNA,在肝脏IRI中的作用也逐渐受到重视。本文分析过氧化物酶体增殖物激活受体、序列相似性家族3基因以及非编码RNA在肝脏IRI中的作用,寻找可能的基因干预靶点,以期预防并减轻患者肝脏IRI,改善术后肝功能。Liver ischemia-reperfusion injury(IRI)is a major complication of hemorrhagic shock,liver transplantation,and other liver surgeries.It’s important to study the targets towards liver IRI for preventing and mitigating the clinical renal injury.It has been reported that the peroxisome proliferator activated receptor gamma(PPARγ)protects the liver against IRI by targeting family with sequence similarity 3 member A(FAM3A).At the meantime,noncoding RNAs,including lncRNAs and miRNAs,have also been reported to play important roles on the process of hepatic IRI.This review briefly discussed the roles and mechanisms of PPARγ,FAM3A and noncoding RNAs in liver IRI,to find potential targets of gene therapy,aiming to prevent and mitigate the liver IRI as well as to improve postoperative liver function.

关 键 词：再灌注损伤 肝脏 非编码RNA 治疗 

分 类 号：R575[医药卫生—消化系统] R657[医药卫生—内科学]